🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting over 82 million infections each year. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options at this time.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Receive Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, gained clearance in concurrent days. This medication, which is additionally indicated for UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This milestone represents a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Outcomes and Global Access

According to findings published in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which uses a dual-drug approach. The study enrolled over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have shared optimism. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for managing the epidemic. This is deemed crucial to alleviate the strain of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.